As mon­key­pox quick­ly spreads, a hand­ful of biotechs spring to ac­tion

At the be­gin­ning of the week, many peo­ple hadn’t ever heard of mon­key­pox. By Fri­day, that all changed — and now a hand­ful of biotech com­pa­nies are reap­ing the ben­e­fits.

Emer­gent Bioso­lu­tions’ $EBS stock jumped more than 10% on Fri­day, four days af­ter the com­pa­ny plumped down $225 mil­lion for the rights to Chimerix’s small­pox vac­cine. Chimerix’s stock $CM­RX was up more than 3.8% on Fri­day. And Bavar­i­an Nordic $BVN­RY — which closed a $119 mil­lion deal with BAR­DA to pro­vide the US gov­ern­ment with freeze-dried dos­es of the Jyn­neos vac­cine — was up near­ly 2.5%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.